Current treatment options for HCC include immune checkpoint inhibitors (ICIs) such as the PD-1 inhibitors pembrolizumab (8) and nivolumab (9), PD-L1 inhibitor atezolizumab also in combination with anti-VEGF (10) as well as anti-CTLA-4 antibody, tremelimumab. This evidence concerns the gene CD274 and hepatocellular carcinoma.